Inventiva S.A.(IVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IVA Inventiva S.A.

Not Yet Opened 10-28 16:00:00 EDT

3.71

+0.03

+0.68%

盘后3.71

+0.000.00%

19:58 EDT

High3.77	Low3.65	Vol946.95K
Open3.69	D1 Closing3.69	Amplitude3.26%
Mkt Cap875.56M	Tradable Cap604.73M	Total Shares236.00M
T/O3.51M	T/O Rate0.58%	Tradable Shares163.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IVA","market":"US","secType":"STK","nameCN":"Inventiva S.A.","latestPrice":3.71,"timestamp":1793217600000,"preClose":3.685,"halted":0,"volume":946949,"hourTrading":{"tag":"盘后","latestPrice":3.71,"preClose":3.71,"latestTime":"19:58 EDT","volume":7419,"amount":27524.7256,"timestamp":1793231919775,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.006784260515603775,"floatShares":163000000,"shares":236000000,"eps":-1.051422,"marketStatus":"Not Yet Opened","change":0.025,"latestTime":"10-28 16:00:00 EDT","open":3.69,"high":3.77,"low":3.65,"amount":3506862.1781026,"amplitude":0.032564,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.051422,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1793260800000},"marketStatusCode":0,"adr":0,"adrRate":1,"listingDate":1594353600000,"exchange":"NASDAQ","adjPreClose":3.685,"preHourTrading":{"tag":"盘前","latestPrice":3.71,"preClose":3.685,"latestTime":"09:27 EDT","volume":1181,"amount":4376.5597204,"timestamp":1793194070064,"change":0.025,"changeRate":0.006784,"amplitude":0.027137},"postHourTrading":{"tag":"盘后","latestPrice":3.71,"preClose":3.71,"latestTime":"19:58 EDT","volume":7419,"amount":27524.7256,"timestamp":1793231919775,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.270977,"impliedVol":3.8684,"impliedVolPercentile":0.9635},"requestUrl":"/m/hq/s/IVA","defaultTab":"news","newsList":[{"id":"2672467712","title":"Inventiva price target raised to $18 from $13 at Truist","url":"https://stock-news.laohu8.com/highlight/detail?id=2672467712","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672467712?lang=en_us&edition=fundamental","pubTime":"2026-10-02 21:05","pubTimestamp":1790946312,"startTime":"0","endTime":"0","summary":"Truist raised the firm’s price target on Inventiva (IVA) to $18 from $13 and keeps a Buy rating on the shares. Following a deep dive into the compa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/inventiva-price-target-raised-to-18-from-13-at-truist-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/inventiva-price-target-raised-to-18-from-13-at-truist-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672711997","title":"Truist Raises Price Target on Inventiva to $18 From $13, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2672711997","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672711997?lang=en_us&edition=fundamental","pubTime":"2026-10-02 19:58","pubTimestamp":1790942321,"startTime":"0","endTime":"0","summary":"Inventiva (IVA) has an average rating of buy and mean price target of $15.75, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671272448","title":"Inventiva (IVA) Receives a Rating Update from a Top Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2671272448","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671272448?lang=en_us&edition=fundamental","pubTime":"2026-09-30 16:55","pubTimestamp":1790758519,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Thomas Smith reiterated a Buy rating on Inventiva yesterday and set a price target of $12.00. The company’s shares closed ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/inventiva-iva-receives-a-rating-update-from-a-top-analyst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/inventiva-iva-receives-a-rating-update-from-a-top-analyst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671424507","title":"Inventiva is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2671424507","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671424507?lang=en_us&edition=fundamental","pubTime":"2026-09-30 00:12","pubTimestamp":1790698320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IVA/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671168852","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Roche Holding AG (OtherRHHVF), Adagene (ADAG) and Inventiva (IVA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2671168852","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671168852?lang=en_us&edition=fundamental","pubTime":"2026-09-29 18:50","pubTimestamp":1790679012,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roche Holding AG (RHHVF), Adagene (ADAG) and Inven...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-roche-holding-ag-otherrhhvf-adagene-adag-and-inventiva-iva-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-roche-holding-ag-otherrhhvf-adagene-adag-and-inventiva-iva-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1046234339.USD","LU0128526141.USD","IVA","LU2539964713.USD","LU0029874061.USD","LU2293690082.USD","LU2293690249.USD","RHHVF","BK4007","BK4588","LABU","HCSG","ADAG","BK4139","BK4137","XBI","BK4581","XLV","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671047215","title":"Inventiva price target raised to $21 from $20 at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2671047215","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671047215?lang=en_us&edition=fundamental","pubTime":"2026-09-29 18:40","pubTimestamp":1790678441,"startTime":"0","endTime":"0","summary":"Canaccord analyst Edward Nash raised the firm’s price target on Inventiva (IVA) to $21 from $20 and keeps a Buy rating on the shares. Inventiva rep...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/inventiva-price-target-raised-to-21-from-20-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/inventiva-price-target-raised-to-21-from-20-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671829804","title":"Analysts Offer Insights on Healthcare Companies: Inventiva (IVA) and Moderna (MRNA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2671829804","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671829804?lang=en_us&edition=fundamental","pubTime":"2026-09-29 13:00","pubTimestamp":1790658033,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Inventiva (IVA) and Moderna (MRNA). Inventiva (IVA...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-inventiva-iva-and-moderna-mrna-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-inventiva-iva-and-moderna-mrna-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4534","IDNA","BK4581","XBI","LU0128526141.USD","BK4568","LU0029874061.USD","BK4533","MRNY","GNOM","XLV","BK4532","LGHT","BK4551","BK4139","BK4585","IVA","BK4137","BK4588","BK4548","MRNX","HCSG","MRNA","LABU","WDNA","BK4501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670289455","title":"France's Inventiva H1 Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2670289455","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670289455?lang=en_us&edition=fundamental","pubTime":"2026-09-28 14:12","pubTimestamp":1790575974,"startTime":"0","endTime":"0","summary":"France's Inventiva H1 net loss narrowsOverviewNet loss for H1 2026 narrowed to 69.5 mln from 175.9 mln in prior yearCompany increased R&D and G&A expenses, driven by clinical development and pre-comme","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nL1N45K05E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670289100","title":"Inventiva H1 EPS $(0.29) Misses $(0.20) Estimate, Sales $23.251K Miss $10.000M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2670289100","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670289100?lang=en_us&edition=fundamental","pubTime":"2026-09-28 14:11","pubTimestamp":1790575878,"startTime":"0","endTime":"0","summary":"Inventiva (NASDAQ:IVA) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.20) by 45 percent. This is a 84.24 percent increase over losses of $(1.84) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/09/62013690/inventiva-h1-eps-0-29-misses-0-20-estimate-sales-23-251k-miss-10-000m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670245104","title":"Inventiva SA Expected to Post a Loss of 49 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2670245104","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670245104?lang=en_us&edition=fundamental","pubTime":"2026-09-26 04:12","pubTimestamp":1790367125,"startTime":"0","endTime":"0","summary":"Inventiva SA <IVA.OQ> expected to post a loss of49cents a share - Earnings PreviewInventiva SAIVA.OQ,IVA.Ois expected to  report resultson September 28 for the period ending June 30 2026LSEG's mean analyst estimate for Inventiva SA is for a loss of 49 cents per share.The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 12 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"The average consensus recommendation for the biotechnology & medical research peer group is also \"Strong Buy\".This summary was machine generated September 25 at 20:12 GMT.  All figures in euros unless otherwise stated.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nL8N45H1HS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669100966","title":"Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Celldex (CLDX) and Inventiva (IVA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669100966","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669100966?lang=en_us&edition=fundamental","pubTime":"2026-09-23 18:50","pubTimestamp":1790160625,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Merck & Company (MRK), Celldex (CLDX) and Inventiv...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-merck-company-mrk-celldex-cldx-and-inventiva-iva-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-merck-company-mrk-celldex-cldx-and-inventiva-iva-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HRTS","PPH","LU0942090050.USD","LU1066051498.USD","LU0868494708.USD","SG9999014542.SGD","LU0965509101.SGD","SG9999013999.USD","LU1291159041.SGD","LU0130102774.USD","LU2361044949.HKD","SG9999014567.USD","LU2023250843.SGD","LU0203347892.USD","FHLC","LU1037948541.HKD","LU0122379950.USD","LU0289739699.SGD","LU1941712264.USD","LU2361045086.USD","BK4559","LU1934455863.HKD","IE000M9KFDE8.USD","LU2125154778.USD","LU0289961442.SGD","LU0320765489.SGD","IE00BBT3K403.USD","LU1032466523.USD","LU1585245621.USD","BK4588","IVA","LU1061106388.HKD","LU1093756168.USD","BK4534","LU1430594728.SGD","LU2461242641.AUD","LU2125154935.USD","LU0069063385.USD","LU0823416689.USD","LU2125909593.SGD","LU1069347547.HKD","FTXH","IE00BLSP4239.USD","LU2089984988.USD","LU0859254822.USD","LU0266013472.USD","LU2491049909.HKD","LU0208291251.USD","VHT","LU0861579265.USD","LU2106854487.HKD","IE00BN8TJ469.HKD","LU2360032135.SGD","SG9999001176.SGD","LU0098860793.USD","LU1066053197.SGD","LU1116320737.USD","IE0009355771.USD","LU1201861249.SGD","IE0002141913.USD","GDOC","IE00BLSP4452.SGD","LU1934455277.USD","LU2491050154.USD","SGXZ57979304.SGD","LU1941712348.USD","LU0472753341.HKD","LU1934455194.USD","LU1929549753.HKD","LU0511384066.AUD","BK4585","IE00BFTCPJ56.SGD","LU1066051811.HKD","IE00BJT1NW94.SGD","LU2468319806.SGD","LU1974910355.USD","LU0211331839.USD","LU0203345920.USD","LU0648001328.SGD","LU0868494617.USD","SG9999014559.SGD","LU0070302665.USD","LU1923622614.USD","BK4533","SG9999014575.USD","LU0965509283.SGD","BK4550","LU0106261372.USD","IE00B4R5TH58.HKD","IHE","BK4516","MRK","LU1989771016.USD","LU2125909247.SGD","LU0058720904.USD","LU1571399168.USD","LU1023059063.AUD","LU0124676726.USD","LU2433249047.HKD","LU1035773651.USD","BK4007","LU0238689110.USD","TRUH","LU0689626769.HKD","LU0265550946.USD","LU2361044865.SGD","IE00BSNM7G36.USD","LU1057294990.SGD","LU2324357040.USD","PAWZ","LU2112291526.USD","BK4139","SG9999015341.SGD","LU1116320901.HKD","LU1162221912.USD","LU1989772840.SGD","LU2357627491.SGD","LU1983299246.USD","LU2023250504.SGD","LU0965509010.AUD","SG9999001176.USD","LU0980610538.SGD","LU1989772923.USD","LU0965508806.USD","LU0289739343.SGD","LU1066051225.USD","IXJ","LU0234572021.USD","LU0006306889.USD","LU1699723380.USD","LU0072461881.USD","SG9999002224.SGD","SG9999015358.SGD","LU1093756325.SGD","LU1037948897.HKD","LU0265550359.USD","BMED","IYH","LU0057025933.USD","LU0320765646.SGD","LU0432979614.USD","LU1917777945.USD","LU0477156953.USD","CLDX","LU2491050071.SGD","JDOC","IE00B1BXHZ80.USD","IE00B2B36J28.USD","SG9999001440.SGD","LU0162691827.USD","SG9999002232.USD","IE00BJJMRZ35.SGD","LU0985320562.USD","RXL","LU0130517989.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668283929","title":"Analysts Offer Insights on Healthcare Companies: Surgery Partners (SGRY), Envista Holdings (NVST) and Inventiva (IVA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2668283929","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668283929?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:10","pubTimestamp":1789729810,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Surgery Partners (SGRY), Envista Holdings (NVST) a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-surgery-partners-sgry-envista-holdings-nvst-and-inventiva-iva-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-surgery-partners-sgry-envista-holdings-nvst-and-inventiva-iva-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IVA","BK4139","XLV","LU0477156797.USD","LU0029874061.USD","LU0130103400.USD","SGRY","BK4185","LU0130518102.USD","BK4581","XBI","LU0648000940.SGD","HCSG","IE0034390439.USD","BK4585","BK4137","LU1201861165.SGD","LU0128526141.USD","BK4588","BK4082","IE00B19Z6F94.USD","LABU","NVST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668995591","title":"Inventiva Currently Down 10 Consecutive Days, on Pace for Longest Losing Streak","url":"https://stock-news.laohu8.com/highlight/detail?id=2668995591","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668995591?lang=en_us&edition=fundamental","pubTime":"2026-09-17 23:11","pubTimestamp":1789657860,"startTime":"0","endTime":"0","summary":"Inventiva SA ADR  is currently at $3.76, down $0.04 or 0.92%--Would be lowest close since July 1, 2026, when it closed at $3.69--On pace for largest percent decrease since Sept. 16, 2026, when it fell 1.81%--Currently down 10 consecutive days; down 22.74% over this period--Longest losing streak on record --Worst 10 day stretch since the 10 days ending June 11, 2026, when it fell 27.34%--Down 19.76% month-to-date--Down 19.25% year-to-date--Down 80.24% from its all-time closing high of $19.00 on Jan. 20, 2021--Down 30.72% from 52 weeks ago , when it closed at $5.42--Down 47.48% from its 52-week closing high of $7.15 on Jan. 23, 2026--Up 10.12% from its 52-week closing low of $3.41 on June 26, 2026--Traded as low as $3.73--Down 1.65% at today's intraday lowAll data as of 11:09:21 AM ETSource: Dow Jones Market Data, FactSet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667964295","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: SanBio Co (OtherSNBIF), Immutep Ltd (OtherPRRUF) and Inventiva (IVA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2667964295","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667964295?lang=en_us&edition=fundamental","pubTime":"2026-09-15 20:20","pubTimestamp":1789474816,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on SanBio Co (SNBIF), Immutep Ltd (PRRUF) and Inventi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-sanbio-co-othersnbif-immutep-ltd-otherprruf-and-inventiva-iva-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-sanbio-co-othersnbif-immutep-ltd-otherprruf-and-inventiva-iva-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","BK4581","PRRUF","LABU","BK4139","LU0029874061.USD","XLV","IVA","BK4585","SNBIF","LU0128526141.USD","BK4137","BK4588","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667918642","title":"Inventiva price target raised to $14 from $11 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2667918642","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667918642?lang=en_us&edition=fundamental","pubTime":"2026-09-15 20:15","pubTimestamp":1789474523,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Seamus Fernandez raised the firm’s price target on Inventiva (IVA) to $14 from $11 and keeps a Buy rating on the shares ahead of...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/inventiva-price-target-raised-to-14-from-11-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/inventiva-price-target-raised-to-14-from-11-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667064432","title":"Guggenheim Sticks to Its Buy Rating for Inventiva (IVA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2667064432","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667064432?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:35","pubTimestamp":1789472141,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Seamus Fernandez maintained a Buy rating on Inventiva today and set a price target of $14.00. According to TipRanks, Fernandez i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-sticks-to-its-buy-rating-for-inventiva-iva-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-sticks-to-its-buy-rating-for-inventiva-iva-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664445528","title":"Inventiva Says All Patients Completed 72-Week Treatment Period in Phase 3 Liver Disease Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2664445528","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664445528?lang=en_us&edition=fundamental","pubTime":"2026-09-03 05:44","pubTimestamp":1788385469,"startTime":"0","endTime":"0","summary":"Inventiva  said late Wednesday that last patient completed the final 72-week visit in its NATiV3 phase 3 trial evaluating lanifibranor for patients with metabolic dysfunction-associated steatohepatitis, a common and progressive chronic liver disease, with moderate to advanced fibrosis.All patients have completed the 72-week treatment period, according to a statement.The study enrolled 1,009 patients in the main cohort and 410 patients in the exploratory cohort, the company said.Inventiva said it expects to report topline results in Q4, and plans to seek regulatory approval in H1 of 2027, if results are favorable.Also, the company updated timing of its H1 financial results to Sept. 28, revised from the prior date of Sept. 25.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664841533","title":"Inventiva announces last patient visit in NATiV3 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2664841533","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664841533?lang=en_us&edition=fundamental","pubTime":"2026-09-03 04:35","pubTimestamp":1788381316,"startTime":"0","endTime":"0","summary":"Inventiva (IVA) announced the last patient has completed their final 72-week visit in the NATiV3 Phase 3 clinical trial evaluating lanifibranor for...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/inventiva-announces-last-patient-visit-in-nativ3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/inventiva-announces-last-patient-visit-in-nativ3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","HYLG","IVA","GDOC","NVIB","IDNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664883867","title":"Inventiva Names Chris Benecchi COO","url":"https://stock-news.laohu8.com/highlight/detail?id=2664883867","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664883867?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:20","pubTimestamp":1788207632,"startTime":"0","endTime":"0","summary":"Inventiva (IVA) said late Monday it appointed Chris Benecchi as chief operating officer.Benecchi was most recently the chief executive officer of Motric Bio, the biopharmaceutical company said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2272731600.USD","BK4588","LU1992135399.USD","BK4585","LU2211815571.USD","COO","IVA","BK4198","BK4139","LU2272731782.SGD","GB00BDT5M118.USD","LU1992135472.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664883852","title":"Inventiva appoints Chris Benecchi as COO","url":"https://stock-news.laohu8.com/highlight/detail?id=2664883852","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664883852?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:15","pubTimestamp":1788207329,"startTime":"0","endTime":"0","summary":"Inventiva (IVA) announced the appointment of Chris Benecchi as COO. Benecchi will lead Inventiva’s operational readiness as the company approaches ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/inventiva-appoints-chris-benecchi-as-coo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/inventiva-appoints-chris-benecchi-as-coo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["COO","LU2272731600.USD","GB00BDT5M118.USD","BK4198","LU2211815571.USD","BK4139","BK4585","LU1992135399.USD","LU2272731782.SGD","LU1992135472.HKD","IVA","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.inventivapharma.com","stockEarnings":[{"period":"1week","weight":0.0451},{"period":"1month","weight":0.051},{"period":"3month","weight":-0.197},{"period":"6month","weight":-0.2535},{"period":"1year","weight":-0.296},{"period":"ytd","weight":-0.2022}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":0.0088},{"period":"3month","weight":0.0413},{"period":"6month","weight":0.0717},{"period":"1year","weight":0.1241},{"period":"ytd","weight":0.1326}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.098872},{"month":2,"riseRate":0.666667,"avgChangeRate":0.043927},{"month":3,"riseRate":0,"avgChangeRate":-0.112386},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.080671},{"month":5,"riseRate":0.5,"avgChangeRate":0.083353},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.137783},{"month":7,"riseRate":0.5,"avgChangeRate":-0.026084},{"month":8,"riseRate":0.428571,"avgChangeRate":0.134717},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.061506},{"month":10,"riseRate":0.714286,"avgChangeRate":0.062272},{"month":11,"riseRate":0.166667,"avgChangeRate":-0.025201},{"month":12,"riseRate":0.833333,"avgChangeRate":0.034174}],"exchange":"NASDAQ","name":"Inventiva S.A.","nameEN":"Inventiva S.A.","securityTypeName":"DR","adrRate":"1:1"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Inventiva S.A.(IVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Inventiva S.A.(IVA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Inventiva S.A.,IVA,Inventiva S.A.股票,Inventiva S.A.股票老虎,Inventiva S.A.股票老虎国际,Inventiva S.A.行情,Inventiva S.A.股票行情,Inventiva S.A.股价,Inventiva S.A.股市,Inventiva S.A.股票价格,Inventiva S.A.股票交易,Inventiva S.A.股票购买,Inventiva S.A.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Inventiva S.A.(IVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Inventiva S.A.(IVA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction